---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-22-071746"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:48:55.853701+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Unicycive Therapeutics reports Q3 2022 net loss of $5.6M and provides pipeline updates

## Summary
- Completed enrollment of pivotal bioequivalence study for RENAZORB; topline data expected by year-end.
- Entered partnership with Lee's Pharmaceutical for RENAZORB in China, receiving $1.0M upfront fee.
- Expects clearance for Phase 1 study of UNI-494 in UK by year-end.
- Net loss for Q3 2022 was $5.6M vs $5.2M in Q3 2021; cash and equivalents totaled $7.0M.

## SEC filing metadata
- accession: 0001213900-22-071746
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/0001213900-22-071746-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/ea168550-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-22-071746
- JSON: https://secwatch.observer/filing/0001213900-22-071746.json
- Plain text: https://secwatch.observer/filing/0001213900-22-071746.txt

## Key facts
- Earnings Releases
  Unicycive Therapeutics, Inc. reported financial results for three months ended September 30, 2022.
  - Period: three months ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, Unicycive Therapeutics, Inc. issued a press release announcing company highlights and financial results for the three months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390022071746/0001213900-22-071746-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.